Cargando…

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies

The use of targeted biologic therapies for hematological malignancies has greatly expanded in recent years. These agents act upon specific molecular pathways in order to target malignant cells but frequently have broader effects involving both innate and adaptive immunity. Patients with hematologica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Little, Jessica S., Weiss, Zoe F., Hammond, Sarah P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706272/ https://www.ncbi.nlm.nih.gov/pubmed/34947040 http://dx.doi.org/10.3390/jof7121058

Ejemplares similares

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies
por: Gamaletsou, Maria N., et al.
Publicado: (2018)

Role of Iron and Iron Overload in the Pathogenesis of Invasive Fungal Infections in Patients with Hematological Malignancies
por: Valković, Toni, et al.
Publicado: (2022)

Invasive Fungal Infections at Presentation of Untreated Hematologic Malignancies: Rare and Elusive
por: Spallone, Amy, et al.
Publicado: (2020)

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
por: Andreescu, Mihaela
Publicado: (2023)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
por: Kyriakidis, Ioannis, et al.
Publicado: (2021)

Surgery for Pulmonary Fungal Infections Complicating Hematological Malignancies
por: Yamamichi, Takashi, et al.
Publicado: (2018)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

Advances in prophylaxis and treatment of invasive fungal infections: perspectives on hematologic diseases
por: Ahn, Hyojin, et al.
Publicado: (2022)

2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
por: Bold, Tyler D, et al.
Publicado: (2019)

Defining Invasive Fungal Infection Risk in Hematological Malignancies: A New Tool for Clinical Practice
por: Rambaldi, Benedetta, et al.
Publicado: (2017)

Risk Prediction and Prognosis of Invasive Fungal Disease in Hematological Malignancies Patients Complicated with Bloodstream Infections
por: Xiao, Han, et al.
Publicado: (2020)

2100. Epidemiology and Risk Factors for Invasive Fungal Infections Among Patients with Hematological Malignancies In Colombia
por: Ortiz-Martínez, Yeimer, et al.
Publicado: (2022)

Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)
por: Akan, Hamdi, et al.
Publicado: (2014)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
por: Daraskevicius, Justinas, et al.
Publicado: (2022)

INVASIVE FUNGAL INFECTIONS IN CHILDREN TREATED FOR HEMATOLOGIC MALIGNANCIES – A FIVE-YEAR SINGLE CENTER EXPERIENCE
por: Buljan, Domagoj, et al.
Publicado: (2022)

Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations
por: Sipsas, Nikolaos V., et al.
Publicado: (2018)

Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies
por: Salih, Zena, et al.
Publicado: (2013)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: Dagher, Hiba, et al.
Publicado: (2022)

Epidemiology and clinical manifestation of fungal infection related to Mucormycosis in hematologic malignancies
por: Noorifard, M, et al.
Publicado: (2015)

Diagnosis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-2)
por: Arıkan Akdağlı, Sevtap, et al.
Publicado: (2014)

Invasive Fungal Infections in Patients with Hematologic Malignancies (Aurora Project): Lights and Shadows During 18-Months Surveillance
por: Montagna, Maria Teresa, et al.
Publicado: (2012)

Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China
por: Zhang, Xiaohui, et al.
Publicado: (2018)

Targeting DNA Repair Pathways in Hematological Malignancies
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
por: Fratta, Elisabetta, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies
por: Petty, Amy J., et al.
Publicado: (2019)

Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies
por: Zeng, Huilan, et al.
Publicado: (2021)

(1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies
por: Azoulay, Elie, et al.
Publicado: (2016)

Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2019)

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR(®) study
por: Maziarz, Richard T., et al.
Publicado: (2016)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Antifungal Strategy in Patients with Invasive Fungal Disease Associated with Hematological Malignancies Based on Risk Stratification
por: Chen, Lijin, et al.
Publicado: (2022)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_32vqlg31ks1opevsqikerr9ask